Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Phillip A. Kubica"'
Autor:
Irene M. Ong, Randy R. Brutkiewicz, Peng Liu, Phillip A. Kubica, Marpe Bam, Seema Siraj, Raj Priya, Shahriar Salamat, Mahua Dey, Montserrat Lara-Velazquez
Publikováno v:
Neuro-oncology Advances
Background Glioblastoma is the most common adult primary brain tumor with near-universal fatality. Major histocompatibility complex (MHC) class I molecules are important mediators of CD8 activation and can be downregulated by cancer cells to escape i
Macrolide and Clindamycin Resistance in Group a Streptococci Isolated From Children With Pharyngitis
Autor:
Gregory P. DeMuri, Ellen R. Wald, Phillip A. Kubica, Alana K. Sterkel, Kurt D. Reed, Megan Duster
Publikováno v:
Pediatric Infectious Disease Journal. 36:342-344
Group A streptococcus (GAS) is responsible for 15%-30% of cases of acute pharyngitis in children. Macrolides such as azithromycin have become popular for treating GAS pharyngitis. We report macrolide resistance rates in a primary care setting in our
Publikováno v:
The American Journal of Case Reports
Patient: Male, 70-year-old Final Diagnosis: Actinomucor elegans Symptoms: Bleeding • dizziness • eschar Medication: — Clinical Procedure: Culture • MALDI • sequencing • tooth extraction Specialty: Infectious Diseases Objective: Rare disea
Autor:
Zhiquan Wang, Erin E. Tapper, Qian Nie, Phillip A. Kubica, Steven M. Offer, Kelly J. Bouchonville, Colbren S. Trogstad-Isaacson, Calvin R. Jerde, Shikshya Shrestha, Rentian Wu, Robert B. Diasio
Publikováno v:
Cancer Research. 78:911-911
Colorectal cancer (CRC) is the third most common cancer and is expected to cause approximately 50,000 deaths in the US in 2017. The antimetabolite 5-fluorouracil (5-FU) is the cornerstone of first-line adjuvant chemotherapy regimens for CRC. Resistan